BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AEterna Zentaris (AEZS): Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming American Society of Clinical Oncology Meeting


5/23/2013 6:44:16 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

QUÉBEC CITY, May 23, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the following posters will be presented on AEZS-108, the Company's lead oncology compound, at the upcoming American Society of Clinical Oncology ("ASCO") annual meeting, which will be held May 31 to June 4, 2013, in Chicago.

Abstract # 5062: "A Phase 1 Dose Escalating Trial of AEZS-108 in Taxane- and Castration-Resistant Prostate Cancer", J. Pinski, A.V. Schally, D. Tsao-Wei, T.B. Dorff, S. Groshen, S. Xiong, D. Quinn, Y. Tai, J. Engel, S.V. Liu.
Presenter: Jacek Pinski, MD, PhD, USC Norris Comprehensive Cancer Center, California
Date & Time: Monday, June 3, 2013, from 8:00 am to 11:45 am (central)
Venue: SHall 2, McCormick Place, Chicago

Abstract # TPS 11124: "A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple-Negative (ER/PR/HER2-Negative) LHRH-R Positive Metastatic Breast Cancer", S. Buchholz, J.B. Engel, A.V. Schally, S. Seitz, O. Ortmann, G. Emons, R.L. Mahtani, S. Glück, C. Vogel, A.J. Montero.
Presenter: Stefan Buchholz, MD, Medical Center University of Regensburg, Germany
Date & Time: Monday, June 3, 2013, from 1:15 pm to 5:00 pm (central)
Venue: S Hall 2, McCormick Place, Chicago

A third abstract (# e15596) on AEZS-108, "A Case Report of a Long-Term Response in a Patient with Urothelial Cancer (UC) Treated with AEZS-108", G. L. Fernandez, A. V. Schally, T. Koru-Sengul, M. Jorda, J. R. Merchan, A. M. Flores, N. L. Block, M. Manoharan, J. Engel, is currently available online on ASCO's website, but will not be presented during a poster session. The abstract reports on the first patient with LHRH-R positive UC treated with AEZS-108 in an ongoing Phase 1 clinical trial.

About AEZS-108 (doxorubicin peptide conjugate)

AEZS-108 represents a new targeting concept in oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. AEZS-108 is the first intravenous drug in advanced clinical development that directs the chemotherapy agent specifically to LHRH-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue. The product has successfully completed Phase 2 studies for the treatment of ovarian and endometrial cancer and the Company is currently initiating a Phase 3 trial in endometrial cancer under a Special Protocol Assessment. AEZS-108 is also in Phase 2 trials in triple-negative breast cancer, prostate cancer and bladder cancer. AEZS-108 has been granted orphan drug designation by the FDA and orphan medicinal product designation from the European Medicines Agency for the treatment of ovarian cancer. Aeterna Zentaris owns worldwide rights to AEZS-108.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information, visit www.aezsinc.com.

SOURCE Aeterna Zentaris Inc.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->